A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results for " Tofacitinib "

Picture of Tofacitinib Diastereomer-1 and 2

Tofacitinib Diastereomer-1 and 2

Unpublished
Reason:
SZ CAT No:SZ-T010063
CAS NoNA
Mol.F.C16H20N6O : C6H8O7
Mol.Wt.312.4 : 192.1
Inv. StatusCustom Synthesis

Chemical Name: 3-((3R,4S)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile bis(2-hydroxypropane-1,2,3-tricarboxylate)

Shipping Temperature: Ambient

HSN Code: 38229010

Country of Origin: India

Smiles: C[C@H]1[C@H](N(C2=C3C(NC=C3)=NC=N2)C)CN(C(CC#N)=O)CC1.C[C@@H]4[C@@H](N(C5=C6C(NC=C6)=NC=N5)C)CN(C(CC#N)=O)CC4.OC(CC(C(O)=O)(O)CC(O)=O)=O.OC(CC(C(O)=O)(O)CC(O)=O)=O

Tofacitinib Diastereomer-1 and 2 is chemically 3-((3R,4S)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile bis(2-hydroxypropane-1,2,3-tricarboxylate). Tofacitinib Diastereomer-1 and 2 is supplied with detailed characterization data compliant with regulatory guideline. Tofacitinib Diastereomer-1 and 2 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Tofacitinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new development or finding in product specification without further noticed.